In our 2019 U.S. Transparency Report, we reported a 1.2% average net price decline for its medicines, marking the third consecutive year of net price reductions. We invested $8.8 billion globally in pharmaceutical research and development, enrolled over 120,000 patients in more than 400 clinical trials, and provided $24.5 billion in discounts, rebates and fees to various healthcare entities. Additionally, through the Janssen CarePath program, we assisted 1.3 million patients with access, affordability and treatment support.
Read the executive summary below, or view the full report here.
All figures according to Johnson & Johnson internal financial accounting. Figures have been rounded.